Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 3, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - July 3, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 27     Next >>     Go To Page:

7/3/15 - Approval for manufacture and sale of XIAFLEX (collagenase clostridium histolyticum) in Japan
Asahi Kasei Pharma today obtained approval for the manufacture and sale of XIAFLEX* injection for the treatment of Dupuytren's contracture in Japan. Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement concluded in March 2011. After conducting a Phase III clinical trial in Japan, Asahi Kasei Pharma filed an
7/3/15 - India,United States : MARKSANS PHARMA takes over TIME-CAP LABORATORIES INC [TendersInfo (India)]
Marksans Pharma Ltd announced that through its wholly owned subsidiary Marksans Pharma Inc, it has purchased 100% stake in US-based generic formulation maker Time-Cap Laboratories Inc for an undisclosed amount. The acquisition is said to boost Marksans presence in the US market, which is the largest pharmaceutical market in the world.
7/3/15 - United States : FDA takes action against unapproved prescription ear drop products [TendersInfo (India)]
The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on these products do not disclose that they lack FDA approval, and health care professionals may not be aware of their unapproved status. Taking enforcement
7/2/15 - FDA Issues Notice on Unapproved, Misbranded Otic Prescription Drug Products
WASHINGTON, July 2 The Department of Health& Human Services published the following notice in the Federal Register from the Food& Drug Administration:. A Notice by the Food and Drug Administration on 07/02/2015. Dates: This notice is effective July 2, 2015.
7/2/15 - FDA takes action against unapproved prescription ear drop products
The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on these products do not disclose that they lack FDA approval, and health care professionals may not be aware of their unapproved status. 'Taking enforcement
7/2/15 - FDA takes action against unapproved prescription ear drop products [Global Data Point]
The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on these products do not disclose that they lack FDA approval, and health care professionals may not be aware of their unapproved status.&# x0D;. Today's act
7/2/15 - Tasly Pharma Raises USD195.8 Million in Public Offering of Bonds Due 2020
Deal Type: Debt Offerings Deal Sub Type: Public Offering Deal Country: China Deal Status: Completed Deal Value: 195.8400 USD. Tasly Pharmaceutical Group Co., Ltd., a manufacturer and distributor of traditional Chinese medicines, has completed the public offering of 12,000,000 convertible corporate bonds, due on June 7, 2020, at a price of CNY100 pe
7/2/15 - The Royal Marsden Teams-up with Boots UK to Offer New Pharmacy Options for Patients; Patients at The Royal Marsden will now be able to benefit from an enhanced prescription service through a new partnership with Boots UK
Release date- 01072015- The Royal Marsden Teams-up with Boots UK to Offer New Pharmacy Options for Patients; Patients at The Royal Marsden will now be able to benefit from an enhanced prescription service through a new partnership with Boots UK. Boots UK also has a number of specially-trained Macmillan Information Pharmacists that are able to suppo
7/2/15 - Unapproved and Misbranded Otic Prescription Drug Products; Enforcement Action Dates
FDA -2015- N-2008 and direct to the appropriate office listed in this ADDRESSES section as follows:. All other communications about this action should be directed to: Kathleen Joyce, Division of Prescription Drugs, Office of Unapproved Drugs and Labeling Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Ha
7/2/15 - US Pharmaceutical Chemicals Market
US demand for pharmaceutical chemicals is forecast to rise 6.1 percent annually to $54 billion in 2019. Merchant market sales primarily to generic drug companies will account for nearly one-third of this total. The remainder of demand will consist of the value of pharmaceutical chemicals produced captively or con tracted for internal use by mak
7/1/15 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Registration of Producers of Drugs...
All comments should be identified with the OMB control number 0910-0045. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
7/1/15 - FDA takes action against unapproved prescription ear drop products
FDA takes action against unapproved prescription ear drop products. The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on these products do not disclose that they lack FDA approval, and health care profession
7/1/15 - Innovus Pharmaceutical Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
SAN DIEGO, CA/ ACCESSWIRE/ July 1, 2015/ Innovus Pharmaceuticals, Inc., www.innovuspharma.com a company focusing on the commercialization of over-the-counter and consumer products for men's and women's health, vitality and respiratory diseases, applauds the June 4th U. S. Food and Drug Administration's Advisory Committee's recommendation for the ap
7/1/15 - Synergy Strips Corp Does Another Acquisition With the Purchase of U.S. Rights for Neuragen(R)
Synergy Strips Corp a consumer health care company, today announced through its wholly owned subsidiary Neuragen Corp the purchase from Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company the U.S. rights related to Neuragen , an innovative OTC product that helps relieve pain caused by diabetic nerve damage.
6/30/15 - Brown Applauds FDA Advance Notice of Proposed Rulemaking on Child-Resistant Packaging, Exposure Warnings for Liquid Nicotine
"This notice of proposed rulemaking is a step in the right direction toward taking the dangers of e-liquids seriously, and I hope that the FDA will take swift action to require child proofing these deadly products in the same way we require childproofing of cleaning solutions and other household products. But the FDA must also help keep these produ
6/30/15 - Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment.
6/30/15 - STIOLTO? RESPIMAT Now Available in the United States for the Treatment of COPD
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO? RESPIMAT Inhalation Spray is now available by prescription at pharmacies across the United States. In May 2015, the U.S. Food and Drug Administration approved STIOLTO RESPIMAT for the long-term, once-daily maintenance treatment of airflow obstruction in patients with ch
6/29/15 - Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, today announced receipt from the United States Patent and Trademark Office of a Notice of Allowance for a non-provisional patent application related to our abuse deterrent LIMITX? Technology platform. About Acura Pharmaceuticals Acura Pharmaceuticals
6/29/15 - Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast
To access the webcast, go to Allergan's Investor Relations Web site at http://ir.allergan.com. Allergan plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervo
6/29/15 - Axxess Pharma Prepares for Strong Revenue Growth in 2nd Half of 2015 Fueled by Their Latest Line of Tapout Products and Up-Listing to the OTCQB Stock Exchange
Axxess Pharma Inc., a company that develops a variety of nutritional supplements and specialty pharmaceutical products through its subsidiary company AllStar Health Brands Inc., is pleased to announce management projects a strong finish to the second half of 2015.. Axxess Pharma is also proud to be a licensee for Tapout, the official fitness and tr
6/29/15 - Pharmacists Rank Nature Made As The Leading Vitamin And Supplement Brand In The U.S.
By a News Reporter-Staff News Editor at Pharma Business Week Nature Made is the leading choice of pharmacists in nine key vitamin and supplement segments, according to a broad survey and ranking of top recommended health products released by U.S. News& World Report, in collaboration with Pharmacy Times. "This marks the 17 consecutive year that P
6/29/15 - Reddy's, Wockhardt, Ohm hit by US recall [DNA : Daily News & Analysis (India)]
Mumbai: The US Food and Drug Administration has recently notified that three Indian pharma companies- Dr Reddy's Laboratories, Wockhardt and Ohm Laboratories- have initiated nationwide voluntary recalls of a number of drugs in the US market. According to a notification on the FDA website, Hyderabad- based Dr Reddy's Labs has initiated recall of...
6/29/15 - Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation (IBS-C)
Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation. Current U.S. Food and Drug Administration- appr
6/27/15 - United States : CARDINAL HEALTH to buy THE HARVARD DRUG GROUP in $1.1 BILLION deal [TendersInfo (India)]
Cardinal Health announced the buyout of Michigan- headquartered The Harvard Drug Group in a deal for $1.12 billion. THDG, which is currently owned by Court Square Capital Partners, is a distributor of generic pharmaceuticals and over-the-counter medications to retail and institutional customers. The Harvard Drug Group aligns perfectly with our...
6/26/15 - Healthy development diagnosis for TCM's future in Europe [China Daily: Europe Weekly]
A traditional Chinese medicine doctor checks the pulse of a patient in the UK. "It is a safe and effective product for cold and flu, and we think it'll be welcomed in the UK when the product is approved," Robert Miller, CEO of Phynova, says. Ban Lan Gen, which is derived from the root of a flowering plant called woad, or Isatis tinctoria, has been
Articles(s): 1 - 25 of 27     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415